» Articles » PMID: 25944989

Epigenetic Regulations of Inflammatory Cyclooxygenase-derived Prostanoids: Molecular Basis and Pathophysiological Consequences

Overview
Publisher Wiley
Specialties Biochemistry
Pathology
Date 2015 May 7
PMID 25944989
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The potential relevance of prostanoid signaling in immunity and immunological disorders, or disease susceptibility and individual variations in drug responses, is an important area for investigation. The deregulation of Cyclooxygenase- (COX-) derived prostanoids has been reported in several immunoinflammatory disorders such as asthma, rheumatoid arthritis, cancer, and autoimmune diseases. In addition to the environmental factors and the genetic background to diseases, epigenetic mechanisms involved in the fine regulation of prostanoid biosynthesis and/or receptor signaling appeared to be an additional level of complexity in the understanding of prostanoid biology and crucial in controlling the different components of the COX pathways. Epigenetic alterations targeting inflammatory components of prostanoid biosynthesis and signaling pathways may be important in the process of neoplasia, depending on the tissue microenvironment and target genes. Here, we focused on the epigenetic modifications of inflammatory prostanoids in physiological immune response and immunological disorders. We described how major prostanoids and their receptors can be functionally regulated epigenetically and consequently the impact of these processes in the pathogenesis inflammatory diseases and the development of therapeutic approaches that may have important clinical applications.

Citing Articles

The Potential of Vouacapanes from Vogel Against COVID-19 Cytokine Storm.

Oliveira L, da Silva A, Thomaz D, Brandao F, da Conceicao E, Valadares M Adv Pharm Bull. 2023; 13(1):150-159.

PMID: 36721819 PMC: 9871284. DOI: 10.34172/apb.2023.016.


Systems biology network reveals the correlation between COX-2 expression and Ch 7q copy number alterations in Ch 11q-deleted pediatric neuroblastoma tumors.

Gradowski Farias da Costa do Nascimento T, Thomazini M, de Franca Junior N, de Castro Poncio L, Fonseca A, de Figueiredo B Genes Cancer. 2022; 13:60-71.

PMID: 36471782 PMC: 9718587. DOI: 10.18632/genesandcancer.225.


Prenatal Activation of Glucocorticoid Receptors Induces Memory Impairment in a Sex-Dependent Manner: Role of Cyclooxygenase-2.

Abul M, Al-Bader M, Mouihate A Mol Neurobiol. 2022; 59(6):3767-3777.

PMID: 35396693 DOI: 10.1007/s12035-022-02820-8.


Crosstalk Between Inflammatory Signaling and Methylation in Cancer.

Das D, Karthik N, Taneja R Front Cell Dev Biol. 2021; 9:756458.

PMID: 34901003 PMC: 8652226. DOI: 10.3389/fcell.2021.756458.


Fetal programming effects of pentaerythritol tetranitrate in a rat model of superimposed preeclampsia.

Man A, Chen M, Zhou Y, Wu Z, Reifenberg G, Daiber A J Mol Med (Berl). 2020; 98(9):1287-1299.

PMID: 32748067 PMC: 7447665. DOI: 10.1007/s00109-020-01949-0.


References
1.
Chen J, Rocken C, Klein-Hitpass L, Gotze T, Leodolter A, Malfertheiner P . Microarray analysis of gene expression in metastatic gastric cancer cells after incubation with the methylation inhibitor 5-aza-2'-deoxycytidine. Clin Exp Metastasis. 2005; 21(5):389-97. DOI: 10.1007/s10585-005-1043-7. View

2.
Ma X, Yang Q, Wilson K, Kundu N, Meltzer S, Fulton A . Promoter methylation regulates cyclooxygenase expression in breast cancer. Breast Cancer Res. 2004; 6(4):R316-21. PMC: 468630. DOI: 10.1186/bcr793. View

3.
Huang Z, Massey J, Via D . Differential regulation of cyclooxygenase-2 (COX-2) mRNA stability by interleukin-1 beta (IL-1 beta) and tumor necrosis factor-alpha (TNF-alpha) in human in vitro differentiated macrophages. Biochem Pharmacol. 2000; 59(2):187-94. DOI: 10.1016/s0006-2952(99)00312-3. View

4.
Tian L, Suzuki M, Nakajima T, Kubo R, Sekine Y, Shibuya K . Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation. Cancer. 2008; 113(6):1396-403. DOI: 10.1002/cncr.23694. View

5.
Smyth E, Grosser T, Wang M, Yu Y, FitzGerald G . Prostanoids in health and disease. J Lipid Res. 2008; 50 Suppl:S423-8. PMC: 2674745. DOI: 10.1194/jlr.R800094-JLR200. View